Cohance Lifesciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.58×	0.73×	0.77×	0.74×	0.73×
	0.82×	0.86×	1.16×	1.16×	1.08×
	5.8%	10.6%	24.9%	33.4%	38.7%
	0.52×	0.52×	0.45×	0.50×	0.71×
	1.42×	1.42×	1.65×	1.10×	1.13×
	2.0%	4.9%	16.4%	15.7%	24.7%
	6.4%	6.4%	14.3%	15.9%	25.2%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.73	0.74	0.77	0.73	0.58
Interest Burden (Pretax/EBIT) ×	1.08	1.16	1.16	0.86	0.82
EBIT Margin %	38.71	33.41	24.86	10.56	5.81
Asset Turnover ×	0.71	0.50	0.45	0.52	0.52
Financial Leverage (Assets/Equity) ×	1.13	1.10	1.65	1.42	1.42
ROE (5-step product, year-end total equity) %	24.68	15.70	16.39	4.89	2.02
ROE (owners' profit / average owners' equity) %	25.21	15.86	14.30	6.39	6.39

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.